Standout Papers

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer 2023 2026 2024154
  1. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer (2023)
    Gerald W. Prager, Julien Taı̈eb et al. New England Journal of Medicine

Immediate Impact

28 standout
Sub-graph 1 of 9

Citing Papers

Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
2025 Standout
Hepatocellular carcinoma: signaling pathways and therapeutic advances
2025 Standout
2 intermediate papers

Works of Loïck Vidot being referenced

Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
2023 Standout

Author Peers

Author Last Decade Papers Cites
Loïck Vidot 189 73 69 11 228
Catherine Leger 196 70 88 10 232
Pierre-Guillaume Poureau 197 66 84 12 237
Nisha L. Jacobs 195 65 75 10 269
Merete Krogh 189 41 68 17 222
Erica N. Heying 217 89 83 10 275
Dong Ma 184 54 75 11 268
Philippe Ronga 173 37 77 13 243
Patrick Texereau 219 49 91 15 274
Ondřej Májek 159 82 56 11 209
Johannes J.M. Kwakman 197 39 63 13 260

All Works

Loading papers...

Rankless by CCL
2026